Verona Tops Up Cashpile As Prospective Partners Circle

GSK is looking to do some dealmaking in the respiratory space and fellow UK firm Verona, which has just inked a $400m loan ahead of an expected US approval for its chronic obstructive pulmonary disease candidate ensifentrine, seems a perfect partner.